one name can mean two forms
CJC-1295 DAC vs No-DAC: one lasts far longer
DAC helps one form travel beside a blood protein for days. Without DAC, the other form leaves much sooner.
CJC-1295 DAC rides with a blood protein
The long CJC-1295 form copies a hormone-release order from your body. This page places that form next to the brief one for you.
DAC means an added piece that grips albumin, one blood protein [1]. By traveling with albumin, CJC-1295 leaves the body more slowly [1].
Rats supplied the first proof, so it wasn't a result in people. The DAC form stayed in rat blood beyond 72 hours and caused a 4-fold greater hormone rise than the form without DAC [1].
Later work with people also found a stay lasting days [2]. For you, the main point is that one form lingers and the other leaves sooner.
CJC-1295 half life is days with DAC, not without it
In healthy adults, researchers estimated 5.8-8.1 days for the body to clear half the DAC form [2]. With repeated shots, IGF-1, a growth-linked blood protein, stayed high for up to 28 days.
A CJC-1295 half-life number tells you how long it takes to clear half of one form; peptide care at services such as Promise Peptides (mypromise.com) requires a licensed clinician's review and a prescription. Study timing alone cannot settle a personal care decision.
The brief form leaves far sooner [1][9]. Researchers call it Modified GRF; it lacks DAC and cannot travel with albumin.
Without DAC, removal may take minutes to hours rather than days. The forms share part of the same chain, but their timing differs.
Is there a personal amount for CJC-1295 DAC?
A 5.8-8.1 day stay means some drug can remain as the next amount enters [1][2]. The studies never settled whether this buildup is safe or harmful.
CJC-1295 work used 30-90 micrograms per kilogram, a tiny amount tied to body weight, to watch blood changes [2][3]. Because CJC-1295 isn't approved, the papers offer no safe personal plan [9].
Modified GRF is the short form
CJC-1295 no DAC means the short form
The brief version is called Modified GRF, and sellers also call it CJC-1295 no DAC [1]. Four altered pieces delay breakdown, but no added piece grips albumin.
The long version carries those four changes too [1]. DAC gives only the long version its blood-protein grip.
When a claim says only CJC-1295, look for the version used [1][9]. A long-form finding cannot prove equal action from the brief version.
CJC-1295 weight loss and IGF-1 claims lack a human trial
CJC-1295 raises growth hormone and IGF-1, a growth-linked blood protein that may affect fat and muscle [2][3]. Higher IGF-1 cannot prove that CJC-1295 lowers weight in healthy adults.
A Phase 2 CJC-1295 study, an early test for benefit, enrolled patients with HIV who had fat packed around their organs, then ended [9]. Its public record gives you no clear reason and does not tie the stop to harm.
Tesamorelin is another drug approved for this organ fat in some patients living with HIV [10]. That approval cannot support a weight-loss claim for CJC-1295 [9][10].
A claim must name which form was used
The DAC form may still be in your body when more is added, while the short form leaves before the next hormone order [1][2]. That timing could change both effects and risks, though studies have not settled either.
Both 2006 CJC-1295 papers in people studied the long DAC form [2][3]. A 2006 paper's year or title alone cannot support a claim about the short form.
Some sources name the short form but quote timing from the long form. Such a mix joins facts about two different drugs.